Inmagene to Host Virtual KOL Event on the Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata
The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the ...
kffhealthnews49m
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
pharmaphorum2h
The future of multiple myeloma is personalised, but we must work together to deliver it
The way forward, then, is to deliver truly personalised medicines and care. For industry, this means developing therapies ...
Data from new national study exposes oral corticosteroids overuse in Canadian patients with severe asthma
The data from the real-world evidence study "Characterizing uncontrolled severe asthma in Canada (ALERT)" was recently ...
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
The Pharma Letter3h
GSK hopes for Arexvy boost after positive Phase III data
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...
GlaxoSmithKline (GSK) Receives a Hold from Goldman Sachs
In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
What's Happening With Pfizer Stock?
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Daily5h
Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine
London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...
Pharmabiz5h
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...
GSK Pharma to expand into oncology, focus on adult vaccines in India
GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...
PipelineReview.com7h
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...